HQY Quote, Financials, Valuation and Earnings

Scienture Holdings, Inc. has a net margin of 18.37% compared to HealthEquity, Inc.'s net margin of -611.42%. HealthEquity, Inc.'s return on equity of 6.84% beat Scienture Holdings, Inc.'s return on equity of -24.88%.

HealthEquity, Inc. has a consensus price target of $120.33, signalling upside risk potential of 21.99%. On the other hand Scienture Holdings, Inc. has an analysts' consensus of -- which suggests that it could grow by 1009.47%. Given that Scienture Holdings, Inc. has higher upside potential than HealthEquity, Inc., analysts believe Scienture Holdings, Inc. is more attractive than HealthEquity, Inc..

HealthEquity, Inc. has a beta of 0.176, which suggesting that the stock is 82.354% less volatile than S&P 500. In comparison Scienture Holdings, Inc. has a beta of 2.959, suggesting its more volatile than the S&P 500 by 195.932%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scienture Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.50 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Scienture Holdings, Inc. pays out 81.44% of its earnings as a dividend. Scienture Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity, Inc. quarterly revenues are $325.8M, which are larger than Scienture Holdings, Inc. quarterly revenues of $590K. HealthEquity, Inc.'s net income of $59.9M is higher than Scienture Holdings, Inc.'s net income of -$3.6M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 59.71x while Scienture Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 6.88x versus 11.94x for Scienture Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Schrödinger, Inc. has a net margin of 18.37% compared to HealthEquity, Inc.'s net margin of -60.37%. HealthEquity, Inc.'s return on equity of 6.84% beat Schrödinger, Inc.'s return on equity of -46.11%.

HealthEquity, Inc. has a consensus price target of $120.33, signalling upside risk potential of 21.99%. On the other hand Schrödinger, Inc. has an analysts' consensus of $27.22 which suggests that it could grow by 53.45%. Given that Schrödinger, Inc. has higher upside potential than HealthEquity, Inc., analysts believe Schrödinger, Inc. is more attractive than HealthEquity, Inc..

HealthEquity, Inc. has a beta of 0.176, which suggesting that the stock is 82.354% less volatile than S&P 500. In comparison Schrödinger, Inc. has a beta of 1.566, suggesting its more volatile than the S&P 500 by 56.591%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrödinger, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Schrödinger, Inc. pays out -- of its earnings as a dividend.

HealthEquity, Inc. quarterly revenues are $325.8M, which are larger than Schrödinger, Inc. quarterly revenues of $54.3M. HealthEquity, Inc.'s net income of $59.9M is higher than Schrödinger, Inc.'s net income of -$32.8M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 59.71x while Schrödinger, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 6.88x versus 5.06x for Schrödinger, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus, Inc. has a net margin of 18.37% compared to HealthEquity, Inc.'s net margin of -330.59%. HealthEquity, Inc.'s return on equity of 6.84% beat Simulations Plus, Inc.'s return on equity of -36.69%.

HealthEquity, Inc. has a consensus price target of $120.33, signalling upside risk potential of 21.99%. On the other hand Simulations Plus, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 9.75%. Given that HealthEquity, Inc. has higher upside potential than Simulations Plus, Inc., analysts believe HealthEquity, Inc. is more attractive than Simulations Plus, Inc..

HealthEquity, Inc. has a beta of 0.176, which suggesting that the stock is 82.354% less volatile than S&P 500. In comparison Simulations Plus, Inc. has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.414%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Simulations Plus, Inc. pays out -48.18% of its earnings as a dividend.

HealthEquity, Inc. quarterly revenues are $325.8M, which are larger than Simulations Plus, Inc. quarterly revenues of $20.4M. HealthEquity, Inc.'s net income of $59.9M is higher than Simulations Plus, Inc.'s net income of -$67.3M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 59.71x while Simulations Plus, Inc.'s PE ratio is 49.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 6.88x versus 5.19x for Simulations Plus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veeva Systems, Inc. has a net margin of 18.37% compared to HealthEquity, Inc.'s net margin of 29.12%. HealthEquity, Inc.'s return on equity of 6.84% beat Veeva Systems, Inc.'s return on equity of 13.78%.

HealthEquity, Inc. has a consensus price target of $120.33, signalling upside risk potential of 21.99%. On the other hand Veeva Systems, Inc. has an analysts' consensus of $315.17 which suggests that it could grow by 30.6%. Given that Veeva Systems, Inc. has higher upside potential than HealthEquity, Inc., analysts believe Veeva Systems, Inc. is more attractive than HealthEquity, Inc..

HealthEquity, Inc. has a beta of 0.176, which suggesting that the stock is 82.354% less volatile than S&P 500. In comparison Veeva Systems, Inc. has a beta of 1.053, suggesting its more volatile than the S&P 500 by 5.265%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veeva Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Veeva Systems, Inc. pays out -- of its earnings as a dividend.

HealthEquity, Inc. quarterly revenues are $325.8M, which are smaller than Veeva Systems, Inc. quarterly revenues of $811.2M. HealthEquity, Inc.'s net income of $59.9M is lower than Veeva Systems, Inc.'s net income of $236.2M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 59.71x while Veeva Systems, Inc.'s PE ratio is 46.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 6.88x versus 13.09x for Veeva Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.